Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Investors sentiment increased to 1.57 in 2019 Q2. Its up 0.29, from 1.28 in 2019Q1. It increased, as 24 investors sold Sangamo Therapeutics, Inc. shares while 32 reduced holdings. 26 funds opened positions while 62 raised stakes. 73.13 million shares or 14.12% more from 64.08 million shares in 2019Q1 were reported.

Dimensional Fund Advsrs Lp has 0.01% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Schroder Invest Mgmt Gru owns 115,841 shares. Rhumbline Advisers holds 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 150,737 shares. Sector Gamma As holds 251,698 shares. Advisory Serv Ntwk Ltd Liability holds 6,267 shares or 0% of its portfolio. Dekabank Deutsche Girozentrale has 152,400 shares. Daiwa Secs Grp has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Credit Agricole S A invested in 2,000 shares. Merriman Wealth Limited Liability Company stated it has 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Janney Montgomery Scott reported 10,378 shares stake. Pub Employees Retirement Sys Of Ohio invested in 121,713 shares or 0.01% of the stock. Bailard reported 175,600 shares or 0.12% of all its holdings. Granahan Invest Mngmt Ma reported 0.05% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Rafferty Asset Mngmt Lc stated it has 0.05% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Maine-based Vigilant Capital Mngmt Ltd Company has invested 0.01% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO).

Sangamo Therapeutics (NASDAQ:SGMO) Stock Upgrade

Sangamo Therapeutics (NASDAQ:SGMO) shares were upped by BidaskScore to a “Hold” rating in analysts note shared with investors on 27 November.

The stock increased 3.46% or $0.36 during the last trading session, reaching $10.76. About 1.32 million shares traded or 16.47% up from the average. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has declined 8.32% since November 29, 2018 and is downtrending. It has underperformed by 8.32% the S&P500.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.30 EPS, down 66.67 % or $0.12 from last year’s $-0.18 per share. After $-0.24 actual EPS reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 25.00 % negative EPS growth.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.25 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Businesswire.com which released: “Sangamo Therapeutics Announces New Scientific Advisory Board – Business Wire” on November 08, 2019, also Finance.Yahoo.com with their article: “We’re Keeping An Eye On Sangamo Therapeutics’s (NASDAQ:SGMO) Cash Burn Rate – Yahoo Finance” published on November 19, 2019, Businesswire.com published: “Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer – Business Wire” on November 01, 2019. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Nasdaq.com and their article: “Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now? – Nasdaq” published on November 26, 2019 as well as Seekingalpha.com‘s news article titled: “Sangamo Q2 revenue down 18% – Seeking Alpha” with publication date: August 07, 2019.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link